Senior Scientist / Director, Biochemistry Novira Therapeutics
You are a hands-on biophysicist, biochemist or biologist who will build a lab to provide expert
biochemistry support to antiviral drug discovery and development projects, including in the areas of HBV
and HIV biology. You will be responsible for generating high quality data in protein analytics, enzyme
kinetics and biochemical and biophysical methods of molecular interactions (e.g. between proteins, nucleic
acids, small molecules, lipids) from your own data and collaborations. Innovative assay development for
evaluation of new drug candidates library screening are also part of the biochemistry lab responsibilities.
This individual or members of the group may initiate novel drug discovery projects as project leaders or
core project team members. Publication of impactful research results is expected.
Ph.D. and at least 3 years of experience as an independent scientist in biology, biochemistry, biophysics or
a related discipline. Hands-on experience with HBV or HIV biochemistry is a plus. Track record of high
impact publications in one or more areas of protein analytics, protein chemistry, enzymology, molecular
interactions or assay development. Highly effective in performing as well as directing scientists in the
establishment of biochemical methods and in establishing methods with collaborators and CROs. Proven
ability to balance multiple and often competing priorities and timelines and to be productive in a fast-paced
team environment. Track record of initiating and maintaining productive scientific collaborations. Proven
record of excellent written, verbal and presentation skills. Experience in applying biochemical or
biophysical methods to drug discovery projects desirable.
Who We Are
Novira Therapeutics is a venture-backed biotechnology company focused on the development and
commercialization of a novel class of antiviral therapeutics. The two lead programs address chronic
Hepatitis B infection and HIV, diseases with enormous worldwide significance, unmet needs, and billion
dollar market potential.
Novira?s oral drugs target the capsid of the virus, and offer a promising treatment option both as
monotherapy and in combination with current standards of care. HBV afflicts over 350 million people
worldwide, with only a single oral class of drugs available. The company?s antivirals potentially address
limitations in treating chronic HBV infection, a disease for which the only class of oral drugs available,
polymerase inhibitors, are rarely curative and often require lifelong treatment, as well as in chronic HIV
infection, a disease for which the continued ability of the virus to mutate inevitably leads to drug-resistant
viral strains. Each of these limitations to the standard of care can potentially be addressed by capsid
inhibitors which feature a new mechanism of action.
In August 2012 the company secured a $23 million Series A financing co-led by new investors 5AM
Ventures and Canaan Partners and joined by WuXi PharmaTech as well as existing investors BioAdvance,
Mid-Atlantic Angel Group, Robin Hood Ventures and Delaware Crossing Investment Group (DCIG). With
this recent financing the company has substantial resources to develop these first-in-class therapies that
offer the promise to substantially improve outcomes in HBV and HIV patients.
Located in the greater Philadelphia area, the company is managed by a team of world class scientific
experts who are making rapid progress with Novira?s lead programs. Given the growing interest of HBV
by numerous pharmaceutical companies and its prevalence in Asia, Novira Therapeutics has begun to
attract the attention of potential corporate partners. With the company on track to enter the clinic in the
beginning of 2014 and the potential for near-term partnering opportunities, the company well is poised to
emerge as a leader in the antivirals arena.
||Radnor, PA |